MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9
In conclusion, this study demonstrated miR-219a-5p plays a crucial role in the development of acquired drug resistance to DDP in NSCLC cells by targeting FGF9 and might be a therapeutic target for DDP resistance in clinical practice.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Study